Profile data is unavailable for this security.
About the company
J. B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its therapeutic categories include gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives and pharmacovigilance. The Company's lozenges products include center-filled, soft-centered lozenges; center-filled, powder lozenges; herbal lozenges, and medicated lozenges. The Company offers a complete range of contrast media products including X-ray, MRI, and ultrasound in India as well as internationally. The Company produces a wide range of dosage forms, such as tablets, capsules, liquids, IV infusions, ampoules, vials, ointments, cold rubs, lozenges and sips. Its brands include Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl O, Nicardia XL, Sporlac EVA and Sporlac G, among others.
- Revenue in INR (TTM)33.85bn
- Net income in INR5.14bn
- Incorporated1976
- Employees5.10k
- LocationJ B Chemicals and Pharmaceuticals LtdCnergy It Park, Appa Saheb Marathe MargMUMBAI 400025IndiaIND
- Phone+91 2 224395200
- Fax+91 2 224395500
- Websitehttps://jbpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Piramal Pharma Ltd | 77.82bn | -333.40m | 161.25bn | 6.30k | -- | -- | 23.18 | 2.07 | -0.3002 | -0.3002 | 63.15 | -- | -- | -- | -- | 12,362,800.00 | -- | -- | -- | -- | 64.29 | -- | -0.4284 | -- | -- | 6.36 | -- | -- | 7.97 | -- | -149.60 | -- | -- | -- |
Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 162.91bn | 1.17k | 43.91 | -- | 38.79 | 13.95 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
Natco Pharma Ltd. | 38.28bn | 12.78bn | 174.36bn | 3.98k | 13.74 | -- | 12.02 | 4.55 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
Sanofi India Ltd | 28.51bn | 6.03bn | 183.34bn | 3.53k | 30.41 | 18.06 | 28.54 | 6.43 | 261.78 | 261.78 | 1,237.96 | 440.80 | 1.51 | 2.24 | 21.86 | -- | 31.84 | 22.42 | 50.35 | 30.21 | 57.88 | 55.69 | 21.15 | 21.03 | 0.897 | 449.47 | 0.0184 | 58.18 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Piramal Enterprises Ltd | 79.98bn | -20.16bn | 187.82bn | 12.22k | -- | -- | -- | 2.35 | -90.77 | -90.77 | 339.88 | -- | -- | -- | -- | 6,545,270.00 | -- | 3.41 | -- | 4.51 | 47.29 | 88.04 | -25.21 | 26.30 | -- | 0.2287 | -- | 22.74 | 6.82 | -4.74 | 528.31 | 14.25 | -24.79 | 4.90 |
Pfizer Ltd | 22.19bn | 5.02bn | 192.34bn | 1.70k | 38.31 | -- | 33.33 | 8.67 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
Alembic Pharmaceuticals Ltd | 61.18bn | 5.90bn | 193.57bn | 14.59k | 32.80 | -- | 22.08 | 3.16 | 30.02 | 30.02 | 311.22 | -- | -- | -- | -- | 4,192,490.00 | -- | 11.45 | -- | 15.39 | 71.10 | 66.43 | 9.80 | 13.65 | -- | 10.21 | -- | 25.26 | 6.54 | 12.54 | -34.35 | -3.69 | -11.61 | 14.87 |
Laurus Labs Ltd | 49.82bn | 1.88bn | 211.38bn | 5.75k | 112.84 | -- | 37.12 | 4.24 | 3.48 | 3.48 | 92.17 | -- | -- | -- | -- | 8,659,934.00 | -- | 11.78 | -- | 19.75 | 51.73 | 48.41 | 4.02 | 14.16 | -- | 2.50 | -- | 12.37 | 22.39 | 23.90 | -4.52 | 36.36 | 20.42 | 31.95 |
J B Chemicals and Pharmaceuticals Ltd | 33.85bn | 5.14bn | 254.97bn | 5.10k | 50.34 | -- | 39.62 | 7.53 | 32.63 | 32.63 | 214.87 | -- | -- | -- | -- | 6,643,323.00 | -- | 15.37 | -- | 18.18 | 65.83 | 60.20 | 15.19 | 15.49 | -- | 15.00 | -- | 31.73 | 29.91 | 17.36 | 6.35 | 24.26 | 83.84 | 54.75 |
Glenmark Pharmaceuticals Ltd | 117.51bn | -12.31bn | 271.59bn | 15.56k | -- | -- | -- | 2.31 | -43.61 | -25.22 | 416.16 | -- | -- | -- | -- | 7,553,779.00 | -- | 4.65 | -- | 6.46 | 61.08 | 60.78 | -9.72 | 6.46 | -- | 1.10 | -- | 10.17 | -5.86 | 4.94 | -118.02 | -- | -10.27 | 4.56 |
Ajanta Pharma Ltd | 40.36bn | 7.36bn | 276.20bn | 7.71k | 37.66 | -- | 31.75 | 6.84 | 58.24 | 58.24 | 319.08 | -- | -- | -- | -- | 5,233,334.00 | -- | 16.13 | -- | 19.52 | 74.16 | 74.01 | 18.23 | 19.22 | -- | 100.64 | -- | 15.93 | 12.02 | 11.92 | -17.50 | 4.64 | -7.86 | -- |
Syngene International Ltd | 35.66bn | 5.00bn | 285.31bn | 6.85k | 57.19 | -- | 31.33 | 8.00 | 12.45 | 12.45 | 88.72 | -- | -- | -- | -- | 5,208,267.00 | -- | 8.80 | -- | 11.95 | 71.36 | 70.68 | 14.03 | 17.00 | -- | 6.88 | -- | -- | 22.61 | 17.54 | 17.33 | 8.74 | 7.34 | 0.00 |
Gland Pharma Ltd | 49.12bn | 6.59bn | 299.86bn | 4.59k | 45.53 | -- | 31.62 | 6.10 | 39.98 | 39.98 | 298.11 | -- | -- | -- | -- | 10,713,810.00 | -- | 15.16 | -- | 16.69 | 60.54 | 53.97 | 13.41 | 26.07 | -- | 46.26 | -- | 0.00 | -17.64 | 17.43 | -35.54 | 19.46 | 21.24 | -- |
IPCA Laboratories Ltd | 71.86bn | 5.64bn | 305.79bn | 16.17k | 54.18 | -- | 32.67 | 4.26 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
Biocon Ltd | 146.13bn | 12.00bn | 307.05bn | 3.41k | 25.58 | -- | 10.18 | 2.10 | 10.03 | 10.03 | 122.21 | -- | -- | -- | -- | 42,877,050.00 | -- | 4.31 | -- | 5.91 | 67.17 | 61.34 | 10.19 | 10.87 | -- | 1.66 | -- | 8.49 | 36.54 | 22.03 | -28.64 | 4.44 | 13.50 | 24.57 |
GlaxoSmithKline Pharmaceuticals Limited | 33.11bn | 5.29bn | 318.45bn | 3.68k | 60.19 | -- | 53.28 | 9.62 | 31.23 | 31.23 | 195.53 | -- | -- | -- | -- | 8,998,269.00 | -- | 9.94 | -- | 16.01 | 60.37 | 54.71 | 15.97 | 11.58 | -- | 447.28 | -- | 196.13 | -0.8025 | 2.35 | 59.58 | 11.62 | -35.79 | 12.83 |
Holder | Shares | % Held |
---|---|---|
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 29 Feb 2024 | 4.89m | 3.15% |
Axis Asset Management Co. Ltd.as of 15 Mar 2024 | 4.12m | 2.66% |
Abrdn Asia Ltd.as of 21 Mar 2024 | 2.83m | 1.82% |
The Vanguard Group, Inc.as of 07 Mar 2024 | 2.69m | 1.73% |
Norges Bank Investment Managementas of 30 Jun 2023 | 2.47m | 1.59% |
Invesco Asset Management (India) Pvt Ltd.as of 29 Feb 2024 | 2.01m | 1.30% |
Canara Robeco Asset Management Co. Ltd.as of 15 Mar 2024 | 1.74m | 1.12% |
Franklin Templeton Asset Management (India) Pvt Ltd.as of 29 Feb 2024 | 1.59m | 1.02% |
Edelweiss Asset Management Ltd.as of 29 Feb 2024 | 1.31m | 0.84% |
HSBC Asset Management (India) Pvt Ltd.as of 29 Feb 2024 | 1.13m | 0.73% |